Long Term Extension Study in Patients With Primary Hyperoxaluria

Running, not enrolling · Phase 3

Conditions studied: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3)

In brief

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.

Key facts

Study ID
NCT04042402
Run by
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
People needed
75
Starts
2019-07-09
Expected to finish
2030-04-01
Last updated by the study team
2025-05-30

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.